Nothing
#' @title Summary Data from the Vemurafenib Study
#'
#' @description
#' The `vemu` and `vemu_wide` data sets provides response information taken
#' from the ``Vemurafenib in multiple nonmelanoma cancers with BRAF v600
#' mutations'' study where, in total, 18 responders were observed among the
#' 84 patients contributing evaluable outcomes for statistical estimation.
#' Observed response rates varied from $42\%$ and $43\%$ for baskets of NSCLC
#' and ECD or LCH to 0 and $4\%,$ for CRC with vemurafenib mono and
#' combination therapies, respectively. Two responders of seven patients, ATC
#' was associated with a $29\%$ response rate, while one responder of eight
#' patients was observed in the cholangiocarcinoma basket. Contrasting
#' favorable results for preliminary vemurafenib activity among NSCLC and ECD
#' or LCH patients with less favorable results for CRC patients, the authors
#' concluded that nonmelanoma tumor types harboring $BRAF^{V600}$ mutations
#' failed to respond uniformly to BRAF-targeted therapy giving credence to
#' more conventional organ-specific nosology when compared to molecular tumor
#' nosology.
#'
#' Later, in the ``Statistical challenges posed by basket trials: sensitivity
#' analysis of the Vemurafenib study'' it was shown that patient-enrollment
#' types we likely drove the negative results for several targets, rather
#' than Vemurafenib itself.
#' @name vemu
#' @aliases vemu_wide
#' @docType data
#' @rdname vemu
#' @references Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY,
#' Wolf J, Raje NS, Diamond EL, Hollebecque A, et al. Vemurafenib in multiple
#' nonmelanoma cancers with braf v600 mutations. New England Journal of
#' Medicine 2015; \strong{373}(8):726
NULL
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.